Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of pegloticase given by two different methods along with methotrexate in adults with uncontrolled gout. This phase 3 trial compares subcutaneous under the skin injections of pegloticase at 18 mg every two weeks with intravenous into a vein injections of pegloticase at 8 mg every two weeks, both combined with weekly methotrexate. The main goal is to see which approach better maintains low serum uric acid levels during the sixth month. Participants will be randomly assigned to receive either pegloticase by subcutaneous injection or by intravenous infusion, both administered every two weeks, alongside oral methotrexate taken weekly. The trial is double-blind, meaning neither participants nor researchers know which form of pegloticase is given. Methotrexate is given orally concurrently. Treatment continues through at least six months with ongoing evaluations. During the study, participants will have regular assessments to monitor their response to treatment, including blood tests to measure serum uric acid levels and pegloticase concentrations. Safety will be closely observed, including monitoring for injection site reactions, infusion reactions, and anaphylaxis up to 48 weeks. The primary outcome measures participants who maintain normalized uric acid levels during Month 6, with follow-up lasting up to 48 weeks. Total participation may extend to the study completion in June 2028.
Actively Recruiting
The trial investigates the long-term safety of avacopan in adults diagnosed with antineutrophil cytoplasmic antibody ANCA-associated vasculitis, a condition requiring immunosuppressive treatment. This phase 4, randomized, double-blind, placebo-controlled study aims to assess treatment-emergent adverse events and other safety markers over a period of up to 5 years. Participants include those newly diagnosed or experiencing a relapse of granulomatosis with polyangiitis or microscopic polyangiitis, with specific antibody and disease activity criteria. Participants are randomly assigned to one of three groups avacopan 30 mg twice daily for 5 years with standard immunosuppressive therapy, avacopan 30 mg twice daily for 1 year followed by placebo for 4 years with standard therapy, or placebo twice daily for 5 years with standard therapy. All participants receive background immunosuppressive care as determined by their doctors. Treatments are administered orally, and the study maintains double-blinding to compare safety and efficacy outcomes across groups. Throughout the study, participants undergo regular safety assessments including vital signs, blood tests, serum chemistry, and urine analysis to monitor any significant changes from baseline. Researchers evaluate adverse events, remission status, kidney function, health survey scores, and glucocorticoid or immunosuppressant use over the 5-year period. The study includes continuous monitoring for serious adverse events, treatment withdrawals, and deaths related to the intervention, ensuring detailed long-term safety data collection.
Actively Recruiting
Researchers are evaluating dapirolizumab pegol DZP as an additional treatment alongside standard care medications for people with moderately to severely active systemic lupus erythematosus SLE. The study aims to determine if DZP can provide meaningful long-term improvement in disease activity compared to placebo. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by UCB Biopharma SRL. Participants are randomly assigned to receive either dapirolizumab pegol or a placebo throughout the treatment period. Both groups continue their standard of care medication during the trial. The treatment is administered at prespecified time points during the study, which lasts for 48 weeks. The study monitors disease activity and safety outcomes during this time. During the study, participants will attend regular visits to assess disease activity using measures such as the British Isles Lupus Assessment Group Disease Activity Index BILAG 2004 and the Systemic Lupus Erythematosus Disease Activity Index 2000 SLEDAI-2K. Researchers will also evaluate fatigue, glucocorticoid dose reduction, and record any treatment-emergent adverse events. Safety follow-up continues up to 54 weeks. Overall participation lasts nearly a year, including treatment and follow-up assessments.